However, when administered in vivo to tumor-bearing C57BL/6 mice, they were able to modulate CD4 + CD25 + Foxp3+ T cells thus correcting the tumor-mediated immune-suppressive microenvironment. This evidence concerns the gene CD4 and neoplasm.